English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe andfeasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a completeresponse (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resectionand additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multipleliver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Livermetastases could not be identified using CT after the end of the sixth course. Grade 1peripheralneuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen waschanged to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after theregimen change.

fukuoka igaku zasshi = hukuoka acta medica

Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.